ATE370738T1 - Verwendung von eplerenon zur behandlung von restenose - Google Patents

Verwendung von eplerenon zur behandlung von restenose

Info

Publication number
ATE370738T1
ATE370738T1 AT00977121T AT00977121T ATE370738T1 AT E370738 T1 ATE370738 T1 AT E370738T1 AT 00977121 T AT00977121 T AT 00977121T AT 00977121 T AT00977121 T AT 00977121T AT E370738 T1 ATE370738 T1 AT E370738T1
Authority
AT
Austria
Prior art keywords
eplerenone
restenoses
treat
pathogenic change
resulting
Prior art date
Application number
AT00977121T
Other languages
English (en)
Inventor
John Delyani
Kenton Fedde
John Funder
Michael Ward
Peter Kanellakis
Alex Bobik
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Application granted granted Critical
Publication of ATE370738T1 publication Critical patent/ATE370738T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
AT00977121T 1999-11-09 2000-11-08 Verwendung von eplerenon zur behandlung von restenose ATE370738T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16439099P 1999-11-09 1999-11-09

Publications (1)

Publication Number Publication Date
ATE370738T1 true ATE370738T1 (de) 2007-09-15

Family

ID=22594274

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00977121T ATE370738T1 (de) 1999-11-09 2000-11-08 Verwendung von eplerenon zur behandlung von restenose

Country Status (9)

Country Link
US (1) US20040067916A1 (de)
EP (1) EP1227804B1 (de)
JP (1) JP2003513913A (de)
AT (1) ATE370738T1 (de)
AU (2) AU1480301A (de)
CA (1) CA2390561A1 (de)
DE (1) DE60036122T2 (de)
ES (1) ES2288487T3 (de)
WO (1) WO2001034132A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1368009A2 (de) * 2000-07-27 2003-12-10 Pharmacia Corporation Aldosteron-blocker zur behandlung oder vorbeugung von entzündungsverwandten störungen
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
JP4270549B2 (ja) * 2002-04-22 2009-06-03 財団法人乙卯研究所 血管性疾患の治療のための医薬
WO2004041289A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Cardiovascular protection using anti-aldosteronic progestins
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
US20050014732A1 (en) * 2003-03-14 2005-01-20 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-diabetic agent
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
EP1853261B1 (de) 2005-03-03 2017-01-11 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
EP2582365B1 (de) * 2010-06-16 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Zusammensetzungen zur stimulierung der reepithelialisation während der wundheilung
JP5953035B2 (ja) * 2011-11-28 2016-07-13 学校法人慶應義塾 病理診断支援装置、病理診断支援方法、及び病理診断支援プログラム
WO2016141182A1 (en) * 2015-03-03 2016-09-09 Yee Richard W Compositions and methods for treating ocular diseases
US20190328753A1 (en) * 2015-03-03 2019-10-31 Richard W. Yee Compositions and methods for treating ocular diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
AU6039296A (en) * 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist
WO2000010552A2 (en) * 1998-08-24 2000-03-02 Global Vascular Concepts, Inc. Use of anti-angiogenic agents for inhibiting vessel wall injury

Also Published As

Publication number Publication date
ES2288487T3 (es) 2008-01-16
EP1227804B1 (de) 2007-08-22
CA2390561A1 (en) 2001-05-17
JP2003513913A (ja) 2003-04-15
DE60036122D1 (de) 2007-10-04
WO2001034132A3 (en) 2002-01-24
EP1227804A2 (de) 2002-08-07
US20040067916A1 (en) 2004-04-08
AU2005229683A1 (en) 2005-12-01
WO2001034132A2 (en) 2001-05-17
AU1480301A (en) 2001-06-06
DE60036122T2 (de) 2008-05-15

Similar Documents

Publication Publication Date Title
DE60036122D1 (de) Verwendung von eplerenon zur behandlung von restenose
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE316785T1 (de) Jak-3 hemmer zur behandlung von allergischen störungen
HUS1600020I1 (hu) Módosított VIII-as faktor
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
DE60027564D1 (de) Tek-antagonisten
ATE548354T1 (de) Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
MY121136A (en) Novel heterocyclic sulfonamides.
ATE438404T1 (de) Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
DE60025639D1 (de) Substituierte diazepan
PL1608685T3 (pl) Antagoniści VEGF do leczenia cukrzycy
DE69815788D1 (de) Verwendung von Des-Aspartate Angiotensin I zur Herstellung eines Arzneimittels zur Vorbeugung und Behandlung von Atherosclerose, Neointimabildung und Restenose
ATE517617T1 (de) Behandlung von parkinson erkrankung mit kape
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60023139D1 (de) Verwendung von il6r- il6 chimären für die behandlung von neurodegenerativen erkankungen
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
ATE338566T1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer- kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DE60318081D1 (de) Verwendung von brimonidine zur behandlung von dementia und morbus parkinson
ATE432359T1 (de) Modulation der s6-kinaseaktivität zur behandlung von adipositas
ATE311901T1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties